|Videos|February 9, 2021
Management of Early-Stage Breast Cancer
Author(s)Cancer Network Staff
Advertisement
Insights on approaching the presented case pre- and post- the COVID-19 pandemic and the multidisciplinary management of early-stage HR+, HER2- breast cancer.
Advertisement
Related to this article
Data from the phase 3 HER2CLIMB-05 study support the FDA approval of tucatinib-based maintenance treatment in HER2-positive metastatic breast cancer.
In the phase 3 evERA trial, interim overall survival data showed a positive trend in favor of giredestrant/everolimus vs endocrine therapy plus everolimus.
10-year CHN HYPOPMRT data show 3-week postmastectomy RT with nodal irradiation maintains locoregional control without added severe late toxicity.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Tucatinib Combo as Maintenance in HER2+ Breast Cancer
2
Selinexor-Based Quadruplet Targets Myeloma After T-Cell Redirecting Therapy
3
Personalized Vaccines May Have Utility Across All Lung Cancer Stages
4
Firmonertinib Misses PFS End Point in First-Line EGFR Exon 20 NSCLC
5